Werbung
Werbung

DNTH

DNTH logo

Dianthus Therapeutics, Inc. Common Stock

38.19
USD
Gesponsert
+0.11
+0.29%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Vor-Markt

38.30

+0.11
+0.28%

DNTH Ergebnisberichte

Positives Überraschungsverhältnis

DNTH übertreffen die 21 der letzten 30Schätzungen.

70%

Nächster Bericht

Datum des nächsten Berichts
09. März 2026
Estimate for Q4 25 (Revenue/ EPS)
$406.90K
/
-$1.08
Implizierte Änderung von Q3 25 (Revenue/ EPS)
+2.75%
/
+11.34%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
-59.27%
/
+33.33%

Dianthus Therapeutics, Inc. Common Stock earnings per share and revenue

On 05. Nov. 2025, DNTH reported earnings of -0.97 USD per share (EPS) for Q3 25, missing the estimate of -0.87 USD, resulting in a -10.28% surprise. Revenue reached 396.00 tausend, compared to an expected 587.93 tausend, with a -32.64% difference. The market reacted with a +8.00% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 analysts forecast an EPS of -1.08 USD, with revenue projected to reach 406.90 tausend USD, implying an increase of 11.34% EPS, and increase of 2.75% in Revenue from the last quarter.
FAQ
For Q3 2025, Dianthus Therapeutics, Inc. Common Stock reported EPS of -$0.97, missing estimates by -10.28%, and revenue of $396.00K, -32.64% below expectations.
The stock price moved up 8%, changed from $33.73 before the earnings release to $36.43 the day after.
The next earning report is scheduled for 09. März 2026.
Based on 16 analysts, Dianthus Therapeutics, Inc. Common Stock is expected to report EPS of -$1.08 and revenue of $406.90K for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung